header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

O3075 COLLAGEN MENISCUS IMPLANT (CMI): EARLY CLINICAL RESULTS AND IMPLANT ANALYSIS



Abstract

Aims: Collagen meniscus implant (CMI) is a tissue engineering technique for the management of irreparable meniscal lesions. We report early clinical results achieved on 30 patients. The implant was also investigated by ultrastructural and biochemical analysis. Methods: Thirty patients, affected by irreparable meniscal lesions, were arthroscopically treated. Average age at the time of surgery was 38.6 years. Additional procedures included 8 ACL reconstruction, 2 high tibial osteotomy and 1 autologous chondrocyte implantation. All knees were evaluated according to the Lysholm II and Tegner activity scales. MRI was performed 6 and 12 months postoperatively. A biopsy of the implant was performed in occasion of a second arthroscopic look in two patients 6 months after surgery. The specimens, as well as the scaffold before implantation, were studied by light microscopy, TEM, SEM, EDAX microanalysis, HPLC and FACE analysis. Results: Follow up averaged 9.3 months. At 3 months, 27 patients showed an increase in the clinical scores. A progressive uniform signal was evident by MRI. Morphological analysis of the speciments showed hyaline tissue inþltrated by cells and vessels, surrounded by the scaffold þbers. At EDAX microanalysis no calciþcations were detected inside the speciments. Biochemical assays demonstrated the presence of GAG molecules of hyaluronic acid and chondroitinsulphate, that were not present in the scaffold before implantation. Conclusions: Early CMI results are promising and are supported by morphological and biochemical þndings, that indicate enhancement of new meniscal tissue by the scaffold.

Theses abstracts were prepared by Professor Dr. Frantz Langlais. Correspondence should be addressed to him at EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.